Association between genetic polymorphisms of CYP2D6 and outcomes in breast cancer patients with tamoxifen treatment by 諛뺣퀝�슦 et al.
© 2011 The Korean Academy of Medical Sciences.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) 
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
pISSN 1011-8934
eISSN 1598-6357
Association between Genetic Polymorphisms of CYP2D6 and 
Outcomes in Breast Cancer Patients with Tamoxifen Treatment
The aim of the study was to evaluate the association between genetic polymorphisms of 
CYP2D6 and outcomes in breast cancer patients with tamoxifen treatment. We evaluated 
the CYP2D6 genetic polymorphisms in 766 breast cancer patients. Among them, 110 
patients whose samples were prospectively collected before surgery and treated with 
tamoxifen were included to evaluate the association between CYP2D6 and outcomes. The 
genotypes of CYP2D6 were categorized as extensive metabolizer (EM), intermediate 
metabolizer (IM), and poor metabolizer (PM) according to the activity score. The 
clinicopathologic features of 110 patients were not significantly different among the three 
groups except for the T-stage and nodal status. The high T-stage and axillary metastasis 
were more frequent in the PM group. While recurrence-free and overall survival in the PM 
group was poorer than the other groups, there was no significant difference between the 
EM and the IM group. The difference between the PM and the other groups on univariate 
analysis disappeared on multivariate analysis. These conflicting results suggest that the 
clinical value of CYP2D6 polymorphisms is still unclear and more large-sized and 
comprehensively designed trials are necessary.
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INTRODUCTION 
Tamoxifen is a widely used selective estrogen receptor modula-
tor (SERM) in hormone receptor positive breast cancer patients, 
and adjuvant tamoxifen therapy almost reduces the annual re-
currence rate by half and the mortality rate by one third (1).
 The biotransformation of tamoxifen is mainly mediated by 
cytochrome P450 (CYP) family 2, subfamily D, polypeptide 6 
(CYP2D6) and CYP family 3, subfamily A, polypeptide 4/5 (CY-
P3A4/5) (2). Tamoxifen itself has a low affinity to estrogen recep-
tors, but its active metabolite forms, 4-hydroxytamoxifen and 
4-hydroxy-N-desmethyltamoxifen (endoxifen) mainly mediat-
ed by CYP2D6, are more potent than tamoxifen in its antiestro-
genic effect (3-6). Therefore, activity of CYP2D6 is important in 
order to determine steady-state plasma concentrations of endox-
ifen and 4-hydroxytamoxifen (7). The activity of CYP2D6 varies 
according to the genetic polymorphisms of CYP2D6 of which 
allele distribution is different among ethnic groups (8). In West-
ern countries, the CYP2D6*4 allele that may predict a lack of 
CYP2D6 activity exists in about 20% of Caucasians. CYP2D6*4 
variants showed poorer clinical outcomes in adjuvant tamoxi-
fen therapy than wild-type (WT) (9, 10). CYP2D6*10 variants, 
instead of CYP2D6*4 variants, are commonly observed in Asians 
(11, 12), and those genotypes have been considered a potential 
factor for tamoxifen resistance in Asians. A few studies are avail-
able that determine whether the genetic polymorphisms of CY-
P2D6 influences the outcomes of adjuvant tamoxifen therapy in 
Asian populations. However, those studies are limited because 
they only investigated CYP2D6*10 genotypes instead of suffi-
cient identification for other CYP2D6 genotypes (7, 13, 14).
 Therefore, we evaluated various genetic polymorphisms of 
CYP2D6 and compared the treatment outcome to the polymor-
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phism of CYP2D6 in Korean breast cancer patients with adju-
vant tamoxifen treatment.
MATERIALS AND METHODS
Participants and endpoints
The blood samples of 766 patients with breast cancer who un-
derwent surgery at Severance Hospital, Yonsei University Health 
System were enrolled and evaluated for the genotyping study. 
Their blood samplings were obtained between 2002 and 2008. 
 In survival analysis, we excluded the patients with stage IV 
disease at diagnosis, unknown endocrine therapy, non-tamoxi-
fen endocrine therapy, previous cancer history, unknown hor-
mone receptor status or negative hormone receptor status, un-
known metabolizers, bilateral breast cancer cases, and late sam-
pling during the follow-up after surgery in the analysis of clini-
cal outcomes. As such, 110 of 766 patients with hormone recep-
tor positive primary breast cancer who underwent surgery and 
adjuvant tamoxifen therapy between 2002 and 2004 were en-
rolled for survival analysis, and all those 110 blood samples were 
prospectively collected at the time of definitive surgery. The dose 
of tamoxifen therapy was 20 mg/d, and the mean duration of 
tamoxifen therapy was 3.9 yr.
 DNA was obtained from the blood samples using GeneAll 
Exgene blood SV (Geneall Biotechnology, Seoul, Korea) accord-
ing to the manufacturer’s protocol and stored at -80°C in a deep 
freezer until the identification of the genotypes. The patients’ clin-
icopathologic characteristics and survival data were obtained 
retrospectively by reviewing medical records and a regular fol-
low-up. Adjuvant chemotherapy and radiation therapy were 
also given by the disease condition. 
 The primary endpoint was recurrence-free survival (RFS), and 
the secondary endpoint was overall survival (OS). RFS was de-
fined as the time from operation to locoregional recurrence, dis-
tant metastasis, or death from any cause. The occurrence of con-
tralateral breast cancer and primary cancer other than breast 
cancer were censored at the time of the occurrence. OS was de-
fined as the time from operation to death from any cause. 
Ethics statement
The institutional review board of Yonsei University Health Sys-
tem approved this study (4-2009-0483). Informed consents for 
genetic analysis in patients whose blood samples were taken 
before 2005 were waived by the institutional review board ac-
cording to the Enforcement Decree of Bioethic and Saftey Act 
in Korea, and the informed consents for genetic analysis in the 
other patients were obtained.
 
Genotyping
Amplification of the CYP2D6 gene was performed using the prim-
ers 5-GTATCAGGTAGTCACAGTGGCTC-3 and 5-ACTGAGCC-
CTGGGAGGTAGGTA-3 with a 9700 Thermal Cycler (PE Applied 
Biosystems, Foster City, CA, USA), as previously described (11). 
Genotyping of CYP2D6 was performed by the SNaPshot meth-
od to discriminate the CYP2D6 *1, *2, *2L, *3, *4, *5, *10B (*10), 
*14, *18, *21, *41, *49, *52, and *60 alleles (http://www.cypal-
leles. ki.se/cyp2d6.htm). The details of the SNaPshot method 
are contained in a pending patent (PCT, KR2007/003102) (un-
published data).
 To detect the deletion and duplication of the entire CYP2D6 
gene, we performed two long-PCR reactions. The duplicated al-
leles of CYP2D6 were amplified using the primers Dup-F_2 (5´-
CCT CAC CAC AGG ACT GGC CAC C-3´) and Dup_R (5´-CAC 
GTG CAG GGC ACC TAG AT-3´). The resulting amplicon of CY-
P2D6 3,303 bp in length was genotyped for the presence of a du-
plication-specific SNP. For the entire deletion, the CYP2D6 gene 
was amplified using the primers CYP2D6_3 (5´-ACC TCT CTG 
GGC CCT CAG GGA-3´) and 3’2D6*5 (5´-CAG GCA TGA GCT 
AAG GCA CCC AGA C-3´) (15). The resulting amplicon was ana-
lyzed for the presence of CYP2D6*5-specific SNP. Both CYP2D6 
duplication and deletion alleles can be discriminated by the al-
lele-specific SNPs located within the recombinant regions. PCR 
was performed using a 9700 Thermal Cycler (PE Applied Biosys-
tems) with the following conditions: initial denaturation at 94°C 
for 1 min, followed by 35 cycles of 98°C for 20 sec, 64°C for 30 sec, 
72°C for 3 min 30 sec, and a final elongation step at 72°C for 10 min.
Hormone receptor and HER2/neu status
Estrogen receptor (ER), progesterone receptor (PR), and HER2/
neu expressions of primary breast cancer were consecutively 
evaluated from formalin-fixed, paraffin-embedded whole sec-
tions of surgically resected breast cancer specimens using im-
munohistochemistry (IHC). The cut off value for ER and PR pos-
itive was over 10% staining in IHC. An IHC score of three posi-
tive was defined as positive for HER2/neu overexpression.
Grouping of metabolizing activity and statistics
CYP2D6 predicted phenotypes were based on the genotypes by 
the activity score (AS) suggested by previous studies (8, 16). The 
cases were categorized into three groups: the extensive metab-
olizer (EM) group if their sum of AS was ≥ 2, the intermediate 
metabolizer (IM) group if their sum of AS was 1 to < 2, and the 
poor metabolizer (PM) group if their sum of AS was < 1, as de-
scribed elsewhere (17). 
 One-way ANOVA was used for comparing the means of con-
tinuous variables among the EM, IM, and PM groups. A two-
sided, Pearson’s chi-square test or Fisher’s exact test was used 
for analyzing of the categorical variables among the three groups. 
The incidence of CYP2D6 metabolizer groups in the current 
study was compared with that of the previous study, which was 
reported by Ramon y Cajal et al. (18). The statistical comparison 
between the two studies according to AS was performed with 
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chi-square test using weighted cases.
 The effects of CYP2D6 predicted phenotypes on RFS and OS 
were evaluated by the Kaplan-Meier method and log rank test. 
A Cox-proportional hazard model was used to determine factors 
associated with RFS. A P value less than 0.05 was considered as 
a statistically significant level. The statistical analysis was carried 
out using PASW statistics 17.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
The mean age of the 766 patients at diagnosis was 47.9 yr (range, 
20-86 yr). Two hundred and eighteen of the 766 patients (28.5%) 
were *1/*10 and it was the most common CYP2D6 genotype in 
the current study. This is followed by *10/*10, *1/*1, *2/*10, *1/ 
*2, and *5/*10, showing a frequency of 143 (18.7%), 102 (13.3%), 
75 (9.7%), 60 (7.8%), and 42 (5.5%), respectively. When we com-
pared the frequency of CYP2D6 genotypes in the current study 
with that in healthy Korean people reported in a previous study 
(11), the frequency of the major genotypes between the two groups 
was similar (Table 1). The frequency of other genotypes in the 
current study is shown in Table 1. There were only two patients 
of the heterozygous *4 genotype in this study. The frequencies 
of PM, IM, and EM were 6.7%, 69.0%, and 24.3%, respectively, 
and the frequency of the metabolizer groups according to AS was 
compared with that of Western breast cancer patients (Table 2) 
(18). We were not able to categorize 30 patients due to their un-
known CYP2D6 activity.
 After the exclusion of 30 patients with unidentified metaboliz-
ers, the clinicopathologic characteristics including age, T-stage, 
Stage IV disease at diagnosis, histologic grade, ER, PR, and HER2 
in 736 patients were not significantly different between the three 
groups. While 47 patients with EM genotype (26.9%) and 177 
Table 1. Frequency of CYP2D6 metabolizers group and polymorphisms
Genotypes
Korean breast cancer  
patients
Healthy Korean  
population*
Frequency % Frequency %
Major genotypes
   *1/*10
   *10/*10
   *1/*1
   *2/*10
   *1/*2
   *5/*10
   *1/*5
 
218
143
102
  74
  60
  42
  25
 
28.5
18.7
13.3
  9.7
  7.8
  5.5
  3.3
 
203
158
  94
  75
  44
  42
  27
 
26.8
20.8
12.4
  9.9
  5.8
  5.5
  3.5
Minor genotypes
   *1/*41   
   *2/*2
   *10/*41
   *2/*5
   *1/*49
   *2/*41
   *10/*49
   *1/*10xN
   *10/*14
   *5/*10xN
   *1/*2xN
   *1/*21
   *2/*5xN
   *1/*14
   *1/*18
   *1/*4
   *10/*10xN
   *10/*18
   *10/*21
   *2/*10xN
   *2/*2xN
   *5/*5
   *10/*18xN
   *1xN/*1xN
   *1xN/*5
   *2/*41xN
   *2/*49
   *5/*41
 
  10
  10
    9
    9
    7
    6
    5
    4
    4
    4
    3
    3
    3
    2
    2
    2
    2
    2
    2
    2
    2
    2
    1
    1
    1
    1
    1
    1
 
  1.3
  1.3
  1.2
  1.2
  0.9
  0.8
  0.7
  0.5
  0.5
  0.5
  0.4
  0.4
  0.4
  0.3
  0.3
  0.3
  0.3
  0.3
  0.3
  0.3
  0.3
  0.3
  0.1
  0.1
  0.1
  0.1
  0.1
  0.1
 
    8
    9
  19
    8
    8
    1
  12
-
    2
-
    7
    1
-
-
-
-
    6
    3
    3
-
-
    2
-
-
-
-
-
    1
 
  1.0
  1.2
  2.5
  1.0
  1.0
  0.1
  1.6
-
  0.3
-
  0.9
  0.1
-
-
-
-
  0.8
  0.4
  0.4
-
-
  0.3
-
-
-
-
-
  0.1
Unknown or others     1   0.1   25   3.3
Total 766 100.0 758 100.0
*Data from reference, Lee et al. (11).
Table 2. Frequency of metabolizer groups according to activity score
Korean breast cancer 
patients
Western breast cancer  
patients*
Frequency % Frequency % P value
EM 179 24.3 31 34.4
IM 508 69.0 49 54.4 0.01
PM   49   6.7 10 11.1
Unknown   30 -   1 -
*Data from reference, Ramon y Cajal et al. (18). EM, extensive metabolizer; IM, inter-
mediate metabolizer; PM, poor metabolizer. 
Table 3. Clinicopathologic characteristics regarding to metabolizer groups in 736 pa-
tients
Parameters
EM 
n = 179 (%)
IM 
n = 508 (%)
PM 
n = 49 (%)
P value
Age (yr) 47.5 ± 10.3 48.2 ± 9.7 46.5 ± 8.5 0.42
T stage
   T0
   Tis
   T1
   T2
   T3
   T4
 
0 (0)
 10 (5.7)
   94 (53.7)
   64 (36.6)
   3 (1.7)
   4 (2.3)
 
  2 (0.4)
  51 (10.3)
248 (50.0)
185 (37.3)
  8 (1.6)
  2 (0.4)
 
   1 (2.0)
   3 (6.1)
   23 (46.9)
   22 (44.9)
0 (0)
0 (0)
0.12
Nodal status
   Negative
   Positive
 
 128 (73.1)
   47 (26.9)
 
316 (64.1)
177 (35.9)
 
   20 (41.7)
   28 (58.3)
< 0.001
Distant metastasis  
   at diagnosis
   7 (3.8) 18 (3.6) 0 (0) 0.39
Histologic grade
   I
   II/III
 
   33 (22.4)
 114 (77.6)
 
  89 (22.3)
311 (77.7)
 
   12 (28.6)
   30 (71.4)
0.64
ER
   Negative
   Positive
 
   59 (35.5)
 107 (64.5)
 
157 (33.6)
310 (66.4)
 
   15 (31.9)
   32 (68.1)
0.86
PR
   Negative
   Positive
 
   78 (47.0)
   88 (53.0)
 
220 (47.1)
247 (52.9)
 
   25 (53.2)
   22 (46.8)
0.72
HER2/neu
   Negative
   Positive
 
 124 (81.6)
   28 (18.4)
 
316 (74.7)
107 (25.3)
 
   35 (77.8)
   10 (22.2)
0.22
EM, extensive metabolizer; IM, intermediate metabolizer; PM, poor metabolizer.
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patients with IM genotype (35.9%) had shown axillary lymph 
node metastasis, 28 patients with PM genotype (58.3%) had ax-
illary lymph node metastasis. The axillary lymph node metasta-
sis was more frequently observed in the PM groups than in the 
IM and EM group, and the difference was statistically significant 
(Table 3). 
 In the analysis of clinical outcomes, we evaluated 110 patients 
whose blood samples were collected at the time of surgery. The 
mean age of the 110 patients was 43.6 yr (range 26-60 yr). The 
clinicopathologic characteristics including age, neoadjuvant 
and adjuvant chemotherapy status, operation type, histologic 
grade, ER, PR, HER2, and status of extended or switching to AI 
therapy were not significantly different among the EM, IM, and 
PM groups, except for the T-stage and nodal metastasis. While 
11 patients (42.3%) in the EM group and 23 patients (30.3%) in 
the IM group showed T2 cancer, six patients (75.0%) in the PM 
group had T2 cancer. The EM and IM groups showed 30.8% and 
25.0% of axillary lymph node metastasis rates, respectively, where-
as the axillary lymph node metastasis rate of the PM group was 
87.5%. The difference in the T-stage and nodal status among EM, 
PM, and IM was statistically significant (T stage; P = 0.02, nodal 
status; P = 0.001). Recurrence occurred in two patients in the 
EM group (7.7%), six patients in the IM group (7.9%), and three 
patients in the PM group (37.5%), respectively. Death events 
were reported in two patients in the IM group (2.6%) and two 
patients in the PM group (25.0%), respectively. The frequency 
of RFS and OS events among the three groups were significantly 
different (RFS events; P = 0.04, OS events; P = 0.03) (Table 4).
 With a median of 74 months of follow-up period (range, 4-85 
months), five year RFS of the EM, IM, and PM group were 91.3%, 
94.2%, and 62.5%, respectively. The Kaplan-Meier survival curves 
illustrated no significant difference in RFS and OS between the 
EM and IM groups (P = 0.96) (Fig. 1). The curves of RFS and OS 
of the PM group showed poorer than those of the other groups, 
respectively, and it was statistically significant (EM vs PM in RFS; 
Cu
m
ul
at
iv
e 
su
rv
iv
al
Cu
m
ul
at
iv
e 
su
rv
iv
al
 Recurrence-free survival  (months) Overall survival  (months)
EM EM
IM IM
PM PM
EM vs IM, P = 0.96 EM vs IM, P = 0.40
EM vs PM, P = 0.02 EM vs PM, P = 0.01
IM vs PM, P = 0.01 IM vs PM, P = 0.008
 0 12 24 36 48 60 72 84  0 12 24 36 48 60 72 84
1.0
0.8
0.6
0.4
0.2
0.0
1.0
0.8
0.6
0.4
0.2
0.0
A B
Fig. 1. Kaplan-Meier Recurrence-free survival and overall survival plots according to metabolizers clustering.
Table 4. Clinicopathologic characteristics regarding to metabolizer groups in 110 pa-
tients treated with tamoxifen therapy
Parameters
EM 
n = 26 (%)
IM 
n = 76 (%) 
PM 
n = 8 (%)
P value
Age (yr) 42.8 ± 6.1 44.2 ± 5.5 40.8 ± 6.5 0.20 
T stage 
   T0
   Tis
   T1
   T2
 
     0 (0)
2 (7.7)
13 (50.0)
11 (42.3)
 
     0 (0)
10 (13.2)
43 (56.6)
23 (30.3)
 
 1 (12.5)
     0 (0)
 1 (12.5)
 6 (75.0)
0.02 
Nodal status 
   Negative 
   Positive 
 
18 (69.2) 
  8 (30.8) 
 
57 (75.0) 
19 (25.0) 
 
 1 (12.5) 
 7 (87.5) 
0.001 
Neoadjuvant  
   chemotherapy (Done) 
1 (3.8) 2 (2.6)  1 (12.5) 0.30 
Operation type 
   Breast conservation  
      surgery 
   Mastectomy 
 
10 (38.5) 
16 (61.5) 
 
22 (28.9) 
53 (71.1) 
 
 3 (37.5) 
 5 (62.5) 
0.65 
Histologic grade 
   I 
   II/III 
 
  5 (22.7) 
17 (77.3) 
 
17 (27.0) 
46 (73.0) 
 
 2 (28.6) 
 5 (71.4) 
0.91 
ER 
   Negative 
   Positive 
 
  3 (11.5) 
23 (88.5) 
 
2 (2.6) 
74 (97.4) 
 
 1 (12.5) 
 7 (87.5) 
0.11 
PR 
   Negative 
   Positive 
 
  5 (19.2) 
21 (80.8) 
 
14 (18.4) 
62 (81.6) 
 
 1 (12.5) 
 7 (87.5) 
1.00 
HER2/neu 
   Negative 
   Positive 
 
24 (92.3) 
2 (7.7) 
 
67 (89.3) 
  8 (10.7) 
 
 7 (87.5) 
 1 (12.5) 
1.00 
Adjuvant chemotherapy  
   (Done) 
20 (76.9) 58 (76.3) 8 (100) 0.29 
Extended aromatase  
   inhibitior therapy 
   None 
   Done 
 
20 (76.9) 
  6 (23.1) 
 
63 (82.9) 
13 (17.1) 
 
 5 (62.5) 
 3 (37.5) 
0.35 
Total RFS events 
   Locoregional recurrence 
   Distant metastasis 
2 (7.7) 
1 (3.8) 
1 (3.8)
6 (7.9) 
     0 (0) 
6 (7.9)
 3 (37.5) 
     0 (0)
 3 (37.5) 
0.04 
Death events      0 (0) 2 (2.6)  2 (25.0) 0.03 
EM, extensive metabolizer; IM, intermediate metabolizer; PM, poor metabolizer; RFS, 
recurrence-free survival.
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P = 0.02, IM vs PM in RFS; P = 0.01, EM vs PM in OS; P = 0.01, IM 
vs PM in OS; P = 0.008) (Fig. 1).
 Table 5 summarized the hazard ratio (HR) and 95% confiden-
tial interval (CI) according to CYP2D6 polymorphisms. The uni-
variate analysis using the Cox regression model showed that IM 
was not a risk factor for tamoxifen resistance (HR 1.06, 95% CI 
0.21-5.25, P = 0.94), but PM was a high risk factor for tamoxifen 
resistance, and it was marginally significant (HR 5.59, 95% CI 
0.93-33.5, P = 0.05). However, the multivariate analysis adjusted 
for metabolizer groups, age, T-stage, nodal status, adjuvant che-
motherapy status, and the status of extended or switching AI 
therapy indicated that all metabolizer groups were not a statis-
tically significant factor associated with RFS (IM; HR 1.32, 95% 
CI 0.25-6.88, P = 0.74, EM; HR 5.24, 95% CI 0.70-39.13, P = 0.10).
DISCUSSION
Some researchers investigated the association between carcino-
genesis and CYP2D6 genotypes, but it is still debatable (19, 20). A 
previous study reported no significant association of CYP2D6*10 
polymorphism with breast cancer risks in Chinese patients (12). 
When we compared the incidence of the major CYP2D6 variants 
which were frequently found in this study with the previous re-
port of a healthy population in Korea (11), the incidence of the 
major CYP2D6 variants in breast cancer patients was similar 
with that of healthy people (Table 1). This suggested that CYP2D6 
polymorphisms may be not associated with the breast cancer 
development.
 Interestingly, the incidence of nodal metastasis seemed to be 
related with the CYP2D6 metabolizer grouping. We observed 
that the PM group showed more aggressive nodal status in the 
present study. The Chinese study also suggested that CYP2D6*10 
is associated with nodal involvements (12). This is similar with 
our results. There is a possibility that the variation of the CYP2D6 
genotype may be associated with nodal metastasis. To validate 
our results, further observational studies are needed.
 Genetic polymorphisms of CYP2D6 are known to be quite dif-
ferent among ethnic groups. In particular, the CYP2D6*10 allele 
is more commonly observed in Asians, while *4 allele is more 
frequently observed in Caucasians (21). When we directly com-
pared the incidence of CYP2D6 metabolizers in our study with 
that of the Western report using chi-square test with the weighted 
case, the difference was statistically significant (Table 2). Previous 
studies demonstrated that PM are found in about 20% among 
Caucasian populations, and the most common allele of PM in that 
population is CYP2D6*4 (22). The allelic frequency of CYP2D6*4 
is 20% in Europeans, 1%-2% in East Asians, and 2%-7% in Afri-
cans (22). There were only two patients carrying the *4 allele in 
the present study, and it was similar with the previous Japanese 
study reporting a rare incidence of the *4 allele (23). IM is the 
most common metabolizer in this study, which was mainly con-
tributed by the *10 allele. This relatively high proportion of IM 
genotypes compared with European populations was similar 
with other reports (14, 22). Because of this ethnic difference in 
CYP2D6 polymorphisms and metabolic activity, the association 
of clinical outcomes with tamoxifen therapy could be different 
among ethnic groups.
 Since the previous report suggested that *4/*4 genotypes tend 
to have a higher risk of disease recurrence (9), a few studies have 
been reported in which patients carrying homogenous *10 al-
leles in Asians are associated with a higher hazard ratio or poor-
er survival outcomes (7, 13, 23). In the current study, we found 
that IM genotypes were not related with poorer RFS compared 
with the EM genotypes. However, RFS of the PM group was sig-
nificantly worse than that of the EM or IM group. It may be due 
to the fact that the PM group has more patients with a larger tu-
mor size and more lymph node metastasis than the others, which 
may strongly influence the difference in RFS and OS between 
the PM and the EM/IM. With the multivariate analysis, no asso-
ciation was found between the clinical outcome and CYP2D6 
metabolizers grouping, and it might suggest that CYP2D6 me-
tabolizer activity may not be a risk factor of tamoxifen resistance. 
In addition, the distinct feature of CYP2D6 polymorphisms among 
ethnicities, the rare incidence of PM in Korean, might be a cru-
cial factor to evaluate the effect of CYP2D6 polymorphisms. Thus, 
further study including a larger population that can obtain suf-
ficient statistical power to discover the implication of the rare 
PM genotypes on tamoxifen resistance in Asians is necessary. 
 Taken together, these results are not enough to support the 
previous reports that suggest a positive correlation between 
CYP2D6 polymorphisms and treatment outcomes in patients 
treated with tamoxifen. Okishiro et al. (14) suggested that the 
CYP2D6*10/*10 genotype, that was mainly related with the IM 
groups in this study, was not associated with the prognosis in 
patients treated with tamoxifen. This supports our results. There-
fore, in contrast to the effect of poor metabolizers such as the *4 
allele, such a reduced level of the active metabolites caused by 
the metabolic activity of the IM including the *10 allele can still 
be effective and sufficient to suppress in vivo tumor recurrence. 
Table 5. Univariate and multivariate analysis for recurrence-free survival between the 
CYP2D6 polymorphisms
Variables HR 95% CI P value
Univariate analysis
   EM
   IM 
   PM 
 
 
1.06
5.59
 
Reference
0.21-5.25
0.93-33.5
 
 
0.94
0.05
Multivariate analysis*  
   EM
   IM 
   PM 
 
 
1.32
5.24
 
Reference
0.25-6.88
0.70-39.13
 
 
0.74
0.10
*Adjustment for age, T stage (< T2 and T2), nodal status, adjuvant chemotherapy sta-
tus, and the status of extended or switching AI therapy. EM, extensive metabolizer; IM, 
intermediate metabolizer; PM, poor metabolizer; HR, hazard ratio; CI, confidence in-
terval.
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In addition, it is also possible that the use of chemotherapy or ex-
tended or switched AI may wash out the effect of reduced CYP2D6 
activity on the prognosis. This possibility is supported by the find-
ings that previous studies evaluating the patients with tamoxi-
fen monotherapy showed a relatively positive finding between 
the CYP2D6 genotype and clinical outcome (9, 10, 23), whereas 
previous studies including the patients receiving combined ad-
juvant therapy such as chemotherapy or ovarian suppression ther-
apy did not demonstrate an association between the CYP2D6 
genotype and clinical outcomes (14, 24, 25). Furthermore, the 
results from ATAC and BIG-1-98 trials presented no relationship 
between CYP2D6 genotypes and clinical outcomes in postmeno-
pausal women with hormone receptor positive breast cancer at 
the 33rd San Antonio Breast Cancer Symposium (26, 27), and 
the recent meta-analysis results could not demonstrate statisti-
cally significant differences according to CYP2D6 genotyping in 
terms of disease-free survival and OS (28). Those results corre-
spond with our results.
 This study has several limitations. First, there has been report-
ed that the distributions of enzyme activity-genotype were dif-
ferent between races; for example, the CYP2D6 *1/*1 genotype 
is usually identified as the reference group but the mean meta-
bolic ratio (MR) of *1/*1 for Korean was significantly lower than 
the MR for Caucasian (29). Thus, there may be a misclassification 
of predicted phenotypes of CYP2D6 based on the activity score 
of genotypes among Caucasian. Further study is needed to asso-
ciate the enzyme activity with known genotypes for each ethnic 
population. Second, the effect of concomitant use of CYP2D6 
inhibitors and the compliance of the use of tamoxifen seems to 
be a crucial factor on the clinical outcomes, and those were val-
idated by a previous study (30). We did not identify cases with 
CYP2D6 inhibitors that may alter the activity of CYP2D6 and the 
patients’ compliance regarding tamoxifen ingestion. Neverthe-
less, to our knowledge, this study identified various genetic poly-
morphisms of CYP2D6, and is one of the largest cohort studies 
of CYP2D6 polymorphisms in Asian breast cancer patients with 
adjuvant endocrine therapy to date. Furthermore, the Food and 
Drug Administration of the United States (FDA) has yet to reach 
a consensus in recommending the testing of CYP2D6 for tamox-
ifen treatment, even though the Roche AmpliChip CYP450® test 
is easily used for the determination of CYP2D6 genotypes and 
was approved by FDA (18). 
 In conclusion, it is too early to confirm that the polymorphism 
of CYP2D6 is associated with tamoxifen resistance in Korean or 
Asian populations. 
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CYP2D6 metabolizes tamoxifen into more potent metabolites, which may influence clinical outcomes of tamoxifen treatment. The 
aim of the study was to evaluate the association between genetic polymorphisms of CYP2D6 and outcomes in breast cancer 
patients with tamoxifen treatment. In the current study, presence of the CYP2D6 poor metabolizer showed poor clinicopathologic 
characteristics and survival in univariate analysis, but not in multivariate analysis, which suggest that the clinical value of CYP2D6 
polymorphisms is still unclear.
